India-based Arna Pharma is contributing to the diversification and expansion of Australia’s pharmaceutical and biotechnology industries through the expansion of its manufacturing plant in New South Wales. The state-of-the-art facility produces high-quality finished medical and pharmaceutical products for domestic and international markets.
Arna Pharma’s investment underscores Australia’s appeal as a thriving hub for health research, development and commercialisation. The company’s manufacturing plant in Sydney is at the heart of its Australian operations and is contributing to the growth of its global business.
A prime destination for health innovation
The healthcare and biotechnology sectors are key drivers of growth in the Australian economy, presenting significant opportunities for innovation, investment, and job creation. By leveraging Australia’s world-class research capabilities, Arna Pharma has been able to enhance its product portfolio, develop new therapies, and bring advanced healthcare solutions to market faster.
In 2025, Arna Pharma’s manufacturing division is set to expand even further, with plans to diversify into niche injectable products, Oral Dispersible Technology (ODT), and topical creams. These new capabilities will allow Arna Pharma to produce specialised products that cater to the growing demand for innovative and accessible healthcare solutions.
Arna Pharma is also constructing a microbiology lab at its NSW facility, aimed at improving research and development of new therapies. The lab is expected to be operational by late 2025, following the completion of the necessary government audits and regulatory approvals. The lab will help the company enhance its capabilities in microbiological testing, offering valuable insights into the development of biologics and novel therapies.
Arna Pharma staff celebrating ‘Arna Day’ at Sydney Harbour.
How Austrade helped
Austrade has provided extensive support to Arna Pharma to help the company invest, innovate and scale in Australia. This support includes market insights, practical assistance including invitations and connections, and advice on visas, grants and incentives.
‘We are proud of the contribution we are making through healthcare and pharmaceuticals innovation,’ says Arna Pharma Managing Director Hemant Gulhane. ‘Australia is an important part of our growth strategy. We appreciate the ongoing support from Austrade as we continue to invest in growing our Australian business.’
A bright future for innovation and growth
Australia remains integral to Arna Pharma’s vision. In the coming years, the company plans to deepen its research initiatives, expand its manufacturing capabilities, and explore new avenues for collaboration with Australian organisations.
With a focus on sustainability, quality and accessibility, Arna Pharma’s Australian operations are set to make an enduring impact on the healthcare landscape.
Learn more about Australia’s health and life sciences sector.
Subscribe to the Investment Update newsletter
Find out about new investment opportunities, insights and investor success stories across Australia.